In pretty short order, the regulatory status of Somaxon Pharmaceuticals Inc.'s insomnia drug Silenor (doxepin) went from having an uncertain timeline to a PDUFA date only two months away, news that surprised Wall Street and sent the company's shares skyrocketing 81.8 percent Friday. (BioWorld Today) Read More
